| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Dr. Greenlee was Program Director for Cancer Surveillance in the Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA. He is currently a lead scientist with the Marshfield Medical Research Foundation, Marshfield, WI.
Ms. Hill-Harmon is an Epidemiologist in the Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Mr. Murray is Manager, Surveillance Data Systems, in the Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Dr. Thun is Vice-President of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMETHODSSELECTED FINDINGSCANCER OCCURRENCE BY...CANCER IN CHILDRENLIMITATIONS AND FUTURE...REFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSSELECTED FINDINGSCANCER OCCURRENCE BY...CANCER IN CHILDRENLIMITATIONS AND FUTURE...REFERENCES |
|---|
|
METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSSELECTED FINDINGSCANCER OCCURRENCE BY...CANCER IN CHILDRENLIMITATIONS AND FUTURE...REFERENCES |
|---|
The observed trend in prostate cancer incidence was not compatible with the selected forecasting model, as rates increased markedly between 1988 and 1992, declined sharply between 1992 and 1995, and leveled off from 1995 to 1997.3 This trend likely reflects extensive use of prostate-specific antigen (PSA) screening in a previously unscreened population and the subsequent increase in diagnoses at an early stage.4 We therefore assumed that the number of prostate cancer cases is approaching the pattern in effect prior to widespread use of PSA screening, and estimated new cases of prostate cancer for 2001 using a linear projection based on data from 1979 to 1989 and 1995 to 1997 only.
Because cancer incidence rates and case counts for 1979 through 1997 were not available for many states, we could not use the methods mentioned earlier to estimate new cases for individual states. To derive these estimates, we relied on state cancer death data and assumed that the ratio of cancer deaths to cancer cases for each state was the same as the ratio for the US.2
Estimated Cancer Deaths
We estimated the number of cancer deaths expected to occur in the US and in each state in the year 2001 using underlying cause-of-death data from death certificates, as reported to the National Center for Health Statistics.5 The recorded numbers of cancer deaths occurring annually from 1979 to 1998 in the US and in each state were fit with autoregressive quadratic models to forecast the number of cancer deaths expected to occur in 2001.
Other Statistics
Mortality statistics for the leading causes of death, the leading causes of death from cancer, and age-adjusted cancer mortality rates for 1930 to 1997 were obtained using data from the National Center for Health Statistics.5 Age-adjusted cancer incidence rates, the probability of developing cancer, and five-year relative survival rates were obtained from the SEER program.3,6
|
SELECTED FINDINGS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSSELECTED FINDINGSCANCER OCCURRENCE BY...CANCER IN CHILDRENLIMITATIONS AND FUTURE...REFERENCES |
|---|
). This estimate does not include carcinoma in situ of any site except urinary bladder, and it does not include basal and squamous cell cancers of the skin. More than a million cases of basal and squamous cell skin cancers, 46,400 cases of breast carcinoma in situ, and 31,400 cases of in situ melanoma are expected to be newly diagnosed in 2001. Estimated numbers of new cancer cases by state are shown in Table 2.
|
|
). The prostate is the leading site for cancer incidence, accounting for 31% of new cancer cases in men. This year 198,100 new cases of prostate cancer are expected to be diagnosed.
|
). Cancers occurring at these sites are expected to account for over 50% of new cancer cases in women. Breast cancer alone is expected to account for 192,200 new cancer cases (31%) in 2001.
Lifetime Probability of Developing Cancer
The lifetime probability of developing cancer is higher in men (43.48%) than in women (38.34%) (Table 3), but women have a higher probability than men of developing any cancer before age 60. In general, however, the probability of developing specific cancers is higher in men than women at all ages, with the exception of breast cancer and cancers specific to women.
|
).7 However, the overall decline has been limited to incidence rates among men, which were heavily influenced by trends in prostate cancer incidence. Declines have also been seen recently for several other leading cancer sites (Figs. 3 and 4).
|
|
|
A significant downturn in the incidence of lung and bronchus cancer in males began in the 1980s; between 1992 and 1997, incidence rates decreased 3.2% per year. Overall incidence rates of female lung and bronchus cancer have been stable since 1991, but rates have begun to decline among women aged 40 to 59.8
Prostate cancer incidence was essentially level from 1995 to 1997, following large annual increases of 17.5% from 1988 to 1992 and a sharp decline of 10.3% per year from 1992 to 1995.3
Expected Numbers of Cancer Deaths
In 2001, an estimated 553,400 Americans are expected to die of cancer—more than 1,500 people a day (Table 4). The estimated numbers of cancer deaths in 2001 by state are shown in Table 5.
|
|
is the reported death rate by state for the years 1993 to 1997 for all cancers combined. The rate varied considerably by state, with the lowest rate in Utah (119 per 100,000 per year) and the highest rate in Washington, DC (208 per 100,000 per year). The average age-adjusted cancer death rate across the entire US was 168 per 100,000 per year.
Cancers of the lung and bronchus, prostate, and colon and rectum combined are expected to contribute 52% of cancer deaths among men in the year 2001 (Fig. 5). Among women, cancers of the lung and bronchus, breast, and colon and rectum are expected to account for 51% of all cancer deaths in 2001 (Fig. 5). Lung cancer has surpassed breast cancer as the leading cause of cancer death in women since 1987 and is expected to account for 25% of all female cancer deaths in 2001.
|
).3 Significant decreases in cancer death rates have occurred among males of all ages, and among females younger than 75 years old.7
|
). The breast cancer death rate among females decreased an average of 2.2% per year between 1990 to 1997; decreases were more pronounced among white women and among younger women. Colon and rectum cancer death rates have been decreasing 1.8% per year on average since 1984, with equally strong declines among men and women.3 Similar to trends in incidence, significant decreases in death rates for lung and bronchus cancer have occurred only among males (on average, 1.7% per year between 1990 and 1997); however, the increase in lung cancer death rates among females has begun to slow recently. Prostate cancer death rates stopped increasing in 1991, and decreased an average of 4.4% annually from 1994 through 1997.3
|
|
). Cancer accounted for 23.2% of all deaths in 1998. Upon examination of causes of death by age and gender, cancer is by far the leading cause of death among women aged 40 to 59 and also ranks first among women aged 60 to 79 (Table 7). The lowest that cancer ranks as a cause of death for any age-gender group is fifth, among men ages 20 to 39.
|
|
present the leading site-specific causes of cancer death for males and females according to age. Leukemia is the most common cause of cancer death among men under age 40, while lung and bronchus cancer is the leading cause of cancer death for men 40 years and older. Prostate cancer is the second most common cause of cancer death among men 60 years and older. Among women, leukemia is the leading cause of cancer death before age 20, but breast cancer and uterine cervical cancer each cause more deaths among women between 20 and 39 years old. Breast cancer is the leading cause of cancer death among women aged 40 to 59. Lung cancer causes the most cancer deaths among women 60 years and older.
|
|
). The number of prostate cancer deaths continued to decline, however, from a peak of 34,902 in 1994 to 32,203 in 1998. The 91,399 lung and bronchus cancer deaths among men in 1998 remain lower than in the peak year of 1993. Colon and rectum cancer deaths among men were highest in 1990, and were slightly lower in 1998 at 28,024.
|
). The upward trend among females is primarily due to sustained increases in the number of deaths from lung and bronchus cancer. The numbers of female deaths from breast cancer, however, have begun to decline. Breast cancer deaths were highest in 1995 at 43,844 and have declined to 41,737 in 1998. The number of colorectal cancer deaths among females has remained fairly constant in recent years. |
CANCER OCCURRENCE BY RACE/ETHNICITY |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSSELECTED FINDINGSCANCER OCCURRENCE BY...CANCER IN CHILDRENLIMITATIONS AND FUTURE...REFERENCES |
|---|
). African Americans have the highest incidence rates of cancer. They are about 60% more likely to develop cancer than Hispanics and Asian/Pacific Islanders and more than twice as likely to develop cancer than American Indians. Between 1990 and 1997, incidence rates for all cancers combined decreased among Caucasians (1.0% per year), Hispanics (1.6% per year), American Indians (0.6% per year), and blacks (0.5% per year), but remained relatively stable among Asian/Pacific Islanders.3
|
African Americans are about 33% more likely to die of cancer than are whites, and more than twice as likely to die from cancer as are Asian/Pacific Islanders, American Indians, and Hispanics. Between 1990 and 1997, mortality rates decreased significantly among whites (0.7% per year), blacks (1.0% per year), Hispanics (0.9% per year), and Asian/Pacific Islanders (0.8% per year), but may be increasing among American Indians.3
Black women are more likely to die of breast and colon and rectum cancers than are women of any other racial or ethnic group, and lung and bronchus cancer death rates are particularly high for both black and white women compared with other racial or ethnic groups. As was seen with incidence rates, black men have the highest death rates of colon and rectum, lung and bronchus, and prostate cancer.3
Cancer Survival
Contributing to the higher death rates among black men and women is a poorer probability of survival once diagnosed with cancer. Blacks are less likely than whites to be diagnosed with cancer at a localized stage, when the disease may be more easily and successfully treated, and more likely to be diagnosed with cancer at a regional or distant stage of disease. This is true for most of the common cancer sites (Fig. 9). Furthermore, for nearly every cancer site, blacks have lower five-year relative survival rates than whites at each stage of diagnosis, suggesting possible influences of differences in treatment, tumor pathology, and comorbid conditions (Fig. 10).
|
|
). This is true for both whites and blacks. Survival has not significant-ly improved for cancers of the uterine cervix, larynx, and oral cavity in the past 25 years.
|
|
CANCER IN CHILDREN |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSSELECTED FINDINGSCANCER OCCURRENCE BY...CANCER IN CHILDRENLIMITATIONS AND FUTURE...REFERENCES |
|---|
). The most commonly occurring cancers in children are leukemias (in particular, acute lymphocytic leukemia), tumors of the central and sympathetic nervous systems, lymphomas, soft-tissue sarcomas, and renal tumors.3 Over the past 25 years, there have been significant improvements in the five-year relative survival rate for many childhood cancers, especially acute lymphocytic and acute myeloid leukemia, non-Hodgkin’s lymphoma, and Wilms’ Tumor (Table 14). Between 1974/1976 and 1989/1996, five-year relative survival rates among children for all cancer sites combined improved from 56% to 75%.3
|
|
|
LIMITATIONS AND FUTURE CHALLENGES |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSSELECTED FINDINGSCANCER OCCURRENCE BY...CANCER IN CHILDRENLIMITATIONS AND FUTURE...REFERENCES |
|---|
Our estimates are based on the most currently available cancer mortality and incidence data; however, these data are three and four years old, respectively, at the time that the estimates are calculated. As such, the effect of large changes occurring in the three or four-year interval between 1997 or 1998 and 2001 cannot be captured by our modeling efforts. Finally, our estimates of new cancer cases are based on incidence rates for the geographic locations that participate in the SEER program and, therefore, may not be representative of the total US.
Despite these limitations, the American Cancer Society estimates do provide evidence of the current patterns of cancer incidence and mortality in the US. Such estimates will assist our continuing efforts to reduce the public health burden of cancer in 21st century.
|
Footnotes |
|---|
This article is also available online at www.cancer.org.
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSSELECTED FINDINGSCANCER OCCURRENCE BY...CANCER IN CHILDRENLIMITATIONS AND FUTURE...REFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  Z. Saidak, R. Mentaverri, and E. M. Brown The Role of the Calcium-Sensing Receptor in the Development and Progression of Cancer Endocr. Rev., April 1, 2009; 30(2): 178 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bandres, N. Bitarte, F. Arias, J. Agorreta, P. Fortes, X. Agirre, R. Zarate, J. A. Diaz-Gonzalez, N. Ramirez, J. J. Sola, et al. microRNA-451 Regulates Macrophage Migration Inhibitory Factor Production and Proliferation of Gastrointestinal Cancer Cells Clin. Cancer Res., April 1, 2009; 15(7): 2281 - 2290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.-K. Kim, J. S. Yang, K. Maiti, J.-I. Hwang, K. Kim, D. Seen, Y. Ahn, C. Lee, B.-C. Kang, H. B. Kwon, et al. A Gonadotropin-Releasing Hormone-II Antagonist Induces Autophagy of Prostate Cancer Cells Cancer Res., February 1, 2009; 69(3): 923 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. FOUNTZILAS, A. BAMIAS, A. KALOGERA-FOUNTZILA, G. KARAYANNOPOULOU, M. BOBOS, E. ATHANASSIOU, K. T. KALOGERAS, C. TOLIS, P. TSEKERIS, P. PAPAKOSTAS, et al. Induction Chemotherapy with Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy in Patients with Inoperable Non-nasopharyngeal Carcinoma of the Head and Neck Anticancer Res, February 1, 2009; 29(2): 529 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Saad, J. L. Lindner, Y. Liu, and J. F. Silverman Lymphangiogenesis in Esophageal Adenocarcinomas--Lymphatic Vessel Density as Prognostic Marker in Esophageal Adenocarcinoma Am J Clin Pathol, January 1, 2009; 131(1): 92 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Chen, H.-H. Lin, T.-A. Chiang, J.-D. Hsu, H.-H. Ho, Y.-C. Lee, and C.-J. Wang Gaseous Nitrogen Oxide Promotes Human Lung Cancer Cell Line A549 Migration, Invasion, and Metastasis via iNOS-Mediated MMP-2 Production Toxicol. Sci., December 1, 2008; 106(2): 364 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yuan, J. Ma, H. Zheng, T. Shi, W. Sun, Q. Zhang, D. Lin, K. Zhang, J. He, Y. Mao, et al. Overexpression of OLC1, Cigarette Smoke, and Human Lung Tumorigenesis J Natl Cancer Inst, November 19, 2008; 100(22): 1592 - 1605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Holder Analysis of chloroethane toxicity and carcinogenicity including a comparison with bromoethane Toxicology and Industrial Health, November 1, 2008; 24(10): 655 - 675. [Abstract] [PDF]
|
|
|
|
|
|
R. E. Coleman, T. A. Guise, A. Lipton, G. D. Roodman, J. R. Berenson, J.-J. Body, B. F. Boyce, L. M. Calvi, P. Hadji, E. V. McCloskey, et al. Advancing Treatment for Metastatic Bone Cancer: Consensus Recommendations from the Second Cambridge Conference Clin. Cancer Res., October 15, 2008; 14(20): 6387 - 6395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Mack, M. W. Redman, K. Chansky, S. K. Williamson, N. C. Farneth, P. N. Lara Jr, W. A. Franklin, Q.-T. Le, J. J. Crowley, and D. R. Gandara Lower Osteopontin Plasma Levels Are Associated With Superior Outcomes in Advanced Non-Small-Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy: SWOG Study S0003 J. Clin. Oncol., October 10, 2008; 26(29): 4771 - 4776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-S. Bats, V. Lavoue, R. Rouzier, C. Coutant, K. Kerrou, and E. Darai Limits of Day-Before Lymphoscintigraphy to Localize Sentinel Nodes in Women with Cervical Cancer Ann. Surg. Oncol., August 1, 2008; 15(8): 2173 - 2179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Schepeler, J. T. Reinert, M. S. Ostenfeld, L. L. Christensen, A. N. Silahtaroglu, L. Dyrskjot, C. Wiuf, F. J. Sorensen, M. Kruhoffer, S. Laurberg, et al. Diagnostic and Prognostic MicroRNAs in Stage II Colon Cancer Cancer Res., August 1, 2008; 68(15): 6416 - 6424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Shugarman, M. E.S. Sorbero, H. Tian, A. K. Jain, and J. S. Ashwood An Exploration of Urban and Rural Differences in Lung Cancer Survival Among Medicare Beneficiaries Am J Public Health, July 1, 2008; 98(7): 1280 - 1287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kaulfuss, M. Grzmil, B. Hemmerlein, P. Thelen, S. Schweyer, J. Neesen, L. Bubendorf, A. G. Glass, H. Jarry, B. Auber, et al. Leupaxin, a Novel Coactivator of the Androgen Receptor, Is Expressed in Prostate Cancer and Plays a Role in Adhesion and Invasion of Prostate Carcinoma Cells Mol. Endocrinol., July 1, 2008; 22(7): 1606 - 1621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tsuruta, L. Pereboeva, M. Breidenbach, D. T. Rein, M. Wang, R. D. Alvarez, G. P. Siegal, P. Dent, P. B. Fisher, and D. T. Curiel A Fiber-Modified Mesothelin Promoter-Based Conditionally Replicating Adenovirus for Treatment of Ovarian Cancer Clin. Cancer Res., June 1, 2008; 14(11): 3582 - 3588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S.M. Diefenbach, S. Gnjatic, P. Sabbatini, C. Aghajanian, M. L. Hensley, D. R. Spriggs, A. Iasonos, H. Lee, B. Dupont, S. Pezzulli, et al. Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission Clin. Cancer Res., May 1, 2008; 14(9): 2740 - 2748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Bhosale, M. Patnana, C. Viswanathan, and J. Szklaruk The Inguinal Canal: Anatomy and Imaging Features of Common and Uncommon Masses RadioGraphics, May 1, 2008; 28(3): 819 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kato, N. Sato, A. Takano, M. Miyamoto, H. Nishimura, E. Tsuchiya, S. Kondo, Y. Nakamura, and Y. Daigo Activation of Placenta-Specific Transcription Factor Distal-less Homeobox 5 Predicts Clinical Outcome in Primary Lung Cancer Patients Clin. Cancer Res., April 15, 2008; 14(8): 2363 - 2370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Mandel, J. W. Tanner, G. R. Lichtenstein, D. C. Metz, D. A. Katzka, G. G. Ginsberg, and M. L. Kochman A Randomized, Controlled, Double-Blind Trial of Patient-Controlled Sedation with Propofol/Remifentanil Versus Midazolam/Fentanyl for Colonoscopy Anesth. Analg., February 1, 2008; 106(2): 434 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kocakoc, A. Kiris, I. Orhan, A. K. Poyraz, H. Artas, and F. Firdolas Detection of Bladder Tumors With 3-Dimensional Sonography and Virtual Sonographic Cystoscopy J. Ultrasound Med., January 1, 2008; 27(1): 45 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Tang, T.-W. Tan, W.-M. Fu, and R.-S. Yang Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis Carcinogenesis, January 1, 2008; 29(1): 35 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Taniwaki, A. Takano, N. Ishikawa, W. Yasui, K. Inai, H. Nishimura, E. Tsuchiya, N. Kohno, Y. Nakamura, and Y. Daigo Activation of KIF4A as a Prognostic Biomarker and Therapeutic Target for Lung Cancer Clin. Cancer Res., November 15, 2007; 13(22): 6624 - 6631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Y. Kim, M. K. Kee, S. A. Chong, and M. J. Nam Galanin Is Up-Regulated in Colon Adenocarcinoma Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2373 - 2378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Visus, D. Ito, A. Amoscato, M. Maciejewska-Franczak, A. Abdelsalem, R. Dhir, D. M. Shin, V. S. Donnenberg, T. L. Whiteside, and A. B. DeLeo Identification of Human Aldehyde Dehydrogenase 1 Family Member A1 as a Novel CD8+ T-Cell Defined Tumor Antigen in Squamous Cell Carcinoma of the Head and Neck Cancer Res., November 1, 2007; 67(21): 10538 - 10545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Y. Chang, S. J. Mentzer, Y. L. Colson, P. A. Linden, M. T. Jaklitsch, S. R. Lipsitz, and D. J. Sugarbaker Factors predicting poor survival after resection of stage IA non-small cell lung cancer. J. Thorac. Cardiovasc. Surg., October 1, 2007; 134(4): 850 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sharma, J. Tammela, X. Wang, H. Arnouk, D. Driscoll, P. Mhawech-Fauceglia, S. Lele, A. L. Kazim, and K. Odunsi Characterization of a Putative Ovarian Oncogene, Elongation Factor 1{alpha}, Isolated by Panning a Synthetic Phage Display Single-Chain Variable Fragment Library with Cultured Human Ovarian Cancer Cells Clin. Cancer Res., October 1, 2007; 13(19): 5889 - 5896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Iorio, R. Visone, G. Di Leva, V. Donati, F. Petrocca, P. Casalini, C. Taccioli, S. Volinia, C.-G. Liu, H. Alder, et al. MicroRNA Signatures in Human Ovarian Cancer Cancer Res., September 15, 2007; 67(18): 8699 - 8707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Coutant, E Barranger, A Cortez, D Dabit, S Uzan, J. Bernaudin, and E Darai Frequency and prognostic significance of HPV DNA in sentinel lymph nodes of patients with cervical cancer Ann. Onc., September 1, 2007; 18(9): 1513 - 1517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Kennedy, A. McWilliams, E. Edell, T. Sutedja, G. Downie, R. Yung, A. Gazdar, and P. N. Mathur Bronchial Intraepithelial Neoplasia/Early Central Airways Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 221S - 233S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Cotrim, F. Hyodo, K.-I. Matsumoto, A. L. Sowers, J. A. Cook, B. J. Baum, M. C. Krishna, and J. B. Mitchell Differential Radiation Protection of Salivary Glands versus Tumor by Tempol with Accompanying Tissue Assessment of Tempol by Magnetic Resonance Imaging Clin. Cancer Res., August 15, 2007; 13(16): 4928 - 4933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Coutant, O. Morel, Y. Delpech, S. Uzan, E. Darai, and E. Barranger Laparoscopic Sentinel Node Biopsy in Cervical Cancer Using a Combined Detection: 5 Years Experience Ann. Surg. Oncol., August 1, 2007; 14(8): 2392 - 2399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ohno, H. Koyama, M. Nogami, D. Takenaka, S. Matsumoto, M. Yoshimura, Y. Kotani, and K. Sugimura Postoperative Lung Function in Lung Cancer Patients: Comparative Analysis of Predictive Capability of MRI, CT, and SPECT Am. J. Roentgenol., August 1, 2007; 189(2): 400 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Mutch, M. Orlando, T. Goss, M. G. Teneriello, A. N. Gordon, S. D. McMeekin, Y. Wang, D. R. Scribner Jr, M. Marciniack, R. W. Naumann, et al. Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer J. Clin. Oncol., July 1, 2007; 25(19): 2811 - 2818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yamamoto, Y. Tomita, Y. Hoshida, E. Morii, T. Yasuda, Y. Doki, K. Aozasa, H. Uyama, H. Nakamura, and M. Monden Expression Level of Hepatoma-Derived Growth Factor Correlates with Tumor Recurrence of Esophageal Carcinoma Ann. Surg. Oncol., July 1, 2007; 14(7): 2141 - 2149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Smyth, C. Gourley, G. Walker, M. J. MacKean, A. Stevenson, A. R.W. Williams, A. A. Nafussi, T. Rye, R. Rye, M. Stewart, et al. Antiestrogen Therapy Is Active in Selected Ovarian Cancer Cases: The Use of Letrozole in Estrogen Receptor-Positive Patients Clin. Cancer Res., June 15, 2007; 13(12): 3617 - 3622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. O'Connor, M. C. Farach-Carson, C. J. Schneider, and D. D. Carson Coculture with Prostate Cancer Cells Alters Endoglin Expression and Attenuates Transforming Growth Factor-{beta} Signaling in Reactive Bone Marrow Stromal Cells Mol. Cancer Res., June 1, 2007; 5(6): 585 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zundelevich, G. Elad-Sfadia, R. Haklai, and Y. Kloog Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid) Mol. Cancer Ther., June 1, 2007; 6(6): 1765 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Frederick, B. A. Helfrich, C. D. Coldren, D. Zheng, D. Chan, P. A. Bunn Jr., and D. Raben Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma Mol. Cancer Ther., June 1, 2007; 6(6): 1683 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hayama, Y. Daigo, T. Yamabuki, D. Hirata, T. Kato, M. Miyamoto, T. Ito, E. Tsuchiya, S. Kondo, and Y. Nakamura Phosphorylation and Activation of Cell Division Cycle Associated 8 by Aurora Kinase B Plays a Significant Role in Human Lung Carcinogenesis Cancer Res., May 1, 2007; 67(9): 4113 - 4122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Wu, Z. Guo, X. Chang, M. S. Kim, J. K. Nagpal, J. Liu, J. M. Maki, K. I. Kivirikko, S. P. Ethier, B. Trink, et al. LOXL1 and LOXL4 Are Epigenetically Silenced and Can Inhibit Ras/Extracellular Signal-Regulated Kinase Signaling Pathway in Human Bladder Cancer Cancer Res., May 1, 2007; 67(9): 4123 - 4129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-y. Tang, Y.-q. Zhu, W.-h. Tao, B. Wei, and X.-l. Lin Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma Postgrad. Med. J., May 1, 2007; 83(979): 338 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Lu, Z. Cai, G. Xiao, E. T. Keller, A. Mizokami, Z. Yao, G. D. Roodman, and J. Zhang Monocyte Chemotactic Protein-1 Mediates Prostate Cancer-Induced Bone Resorption Cancer Res., April 15, 2007; 67(8): 3646 - 3653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Schleicher, C. Poremba, H. Wolters, K.-L. Schafer, N. Senninger, and M. Colombo-Benkmann Gain of Chromosome 8q: A Potential Prognostic Marker in Resectable Adenocarcinoma of the Pancreas? Ann. Surg. Oncol., April 1, 2007; 14(4): 1327 - 1335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Saar, A Meining, A Beer, M Settles, H Helmberger, E Frimberger, E J Rummeny, and T Rosch Prospective study on bright lumen magnetic resonance colonography in comparison with conventional colonoscopy Br. J. Radiol., April 1, 2007; 80(952): 235 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Puppala, C.G. Gairola, and H.I. Swanson Identification of kaempferol as an inhibitor of cigarette smoke-induced activation of the aryl hydrocarbon receptor and cell transformation Carcinogenesis, March 1, 2007; 28(3): 639 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang and A. Chang Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer J. Med. Genet., March 1, 2007; 44(3): 166 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Lagman, N. Rivera, D. Walsh, S. LeGrand, and M. P. Davis Acute Inpatient Palliative Medicine in a Cancer Center: Clinical Problems and Medical Interventions--A Prospective Study American Journal of Hospice and Palliative Medicine, February 1, 2007; 24(1): 20 - 28. [Abstract] [PDF]
|
|
|
|
|
|
C. Suzuki, K. Takahashi, S. Hayama, N. Ishikawa, T. Kato, T. Ito, E. Tsuchiya, Y. Nakamura, and Y. Daigo Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer Mol. Cancer Ther., February 1, 2007; 6(2): 542 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Aghdassi, P. Phillips, V. Dudeja, D. Dhaulakhandi, R. Sharif, R. Dawra, M. M. Lerch, and A. Saluja Heat Shock Protein 70 Increases Tumorigenicity and Inhibits Apoptosis in Pancreatic Adenocarcinoma Cancer Res., January 15, 2007; 67(2): 616 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kato, S. Hayama, T. Yamabuki, N. Ishikawa, M. Miyamoto, T. Ito, E. Tsuchiya, S. Kondo, Y. Nakamura, and Y. Daigo Increased Expression of Insulin-like Growth Factor-II Messenger RNA-Binding Protein 1 Is Associated with Tumor Progression in Patients with Lung Cancer Clin. Cancer Res., January 15, 2007; 13(2): 434 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E S Edell High-grade lesion: what does it tell us? Thorax, January 1, 2007; 62(1): 2 - 3. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gill, A. W. Blackstock, and R. M. Goldberg Colorectal Cancer Mayo Clin. Proc., January 1, 2007; 82(1): 114 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ueda, K. Fukamachi, Y. Matsuoka, N. Takasuka, F. Takeshita, A. Naito, M. Iigo, D. B. Alexander, M. A. Moore, I. Saito, et al. Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas Carcinogenesis, December 1, 2006; 27(12): 2497 - 2510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kyrgiou, G. Salanti, N. Pavlidis, E. Paraskevaidis, and J. P. A. Ioannidis Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments. J Natl Cancer Inst, November 15, 2006; 98(22): 1655 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. L. Griffith, A. Melck, S. J.M. Jones, and S. M. Wiseman Meta-Analysis and Meta-Review of Thyroid Cancer Gene Expression Profiling Studies Identifies Important Diagnostic Biomarkers J. Clin. Oncol., November 1, 2006; 24(31): 5043 - 5051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Bloom, S. L. Stewart, I. Oakley-Girvans, P. J. Banks, and S. Chang Family History, Perceived Risk, and Prostate Cancer Screening among African American Men. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2167 - 2173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.J. Mao, W.V. Giannobile, J.A. Helms, S.J. Hollister, P.H. Krebsbach, M.T. Longaker, and S. Shi Craniofacial Tissue Engineering by Stem Cells Journal of Dental Research, November 1, 2006; 85(11): 966 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hayama, Y. Daigo, T. Kato, N. Ishikawa, T. Yamabuki, M. Miyamoto, T. Ito, E. Tsuchiya, S. Kondo, and Y. Nakamura Activation of CDCA1-KNTC2, Members of Centromere Protein Complex, Involved in Pulmonary Carcinogenesis Cancer Res., November 1, 2006; 66(21): 10339 - 10348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Litman, S. Bhasin, C. L. Link, A. B. Araujo, J. B. McKinlay, and for the Boston Area Community Health Survey Invest Serum Androgen Levels in Black, Hispanic, and White Men J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4326 - 4334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S L El Sharkawy, N F Abbas, M A Badawi, and M A El Shaer Metallothionein isoform II expression in hyperplastic, dysplastic and neoplastic prostatic lesions J. Clin. Pathol., November 1, 2006; 59(11): 1171 - 1174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pectasides, E. Pectasides, A. Psyrri, and T. Economopoulos Treatment Issues in Clear Cell Carcinoma of the Ovary: A Different Entity? Oncologist, November 1, 2006; 11(10): 1089 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Xu, L. Ngo, G. Perez, M. Dokmanovic, and P. A. Marks Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor PNAS, October 17, 2006; 103(42): 15540 - 15545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Takahashi, C. Furukawa, A. Takano, N. Ishikawa, T. Kato, S. Hayama, C. Suzuki, W. Yasui, K. Inai, S. Sone, et al. The Neuromedin U-Growth Hormone Secretagogue Receptor 1b/Neurotensin Receptor 1 Oncogenic Signaling Pathway as a Therapeutic Target for Lung Cancer Cancer Res., October 1, 2006; 66(19): 9408 - 9419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Li and B. C. Tai RNASEL Gene Polymorphisms and the Risk of Prostate Cancer: a Meta-analysis. Clin. Cancer Res., October 1, 2006; 12(19): 5713 - 5719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Munday, M. M. Brennan, and M. Kiupel Altered Expression of {beta}-catenin, E-cadherin, Cycloxygenase-2, and p53 Protein by Ovine Intestinal Adenocarcinoma Cells. Vet. Pathol., September 1, 2006; 43(5): 613 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chung, D. Liou, S. Karlan, A. Waxman, K. Fujimoto, M. Hagiike, and E. H. Phillips Preoperative FDG-PET for Axillary Metastases in Patients With Breast Cancer Arch Surg, August 1, 2006; 141(8): 783 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-a. Yuan, H. H. Simmons, M. K. Robinson, M. Russeva, W. A. Marasco, and G. P. Adams Development of engineered antibodies specific for the Mullerian inhibiting substance type II receptor: a promising candidate for targeted therapy of ovarian cancer. Mol. Cancer Ther., August 1, 2006; 5(8): 2096 - 2105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. O. Hoque, S. Begum, O. Topaloglu, A. Chatterjee, E. Rosenbaum, W. Van Criekinge, W. H. Westra, M. Schoenberg, M. Zahurak, S. N. Goodman, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst, July 19, 2006; 98(14): 996 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-Y. Chung, T. Braunschweig, N. Hu, M. Roth, J. L. Traicoff, Q.-H. Wang, V. Knezevic, P. R. Taylor, and S. M. Hewitt A multiplex tissue immunoblotting assay for proteomic profiling: a pilot study of the normal to tumor transition of esophageal squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1403 - 1408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cappuzzo, L. Toschi, G. Tallini, G. L. Ceresoli, I. Domenichini, S. Bartolini, G. Finocchiaro, E. Magrini, G. Metro, A. Cancellieri, et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib Ann. Onc., July 1, 2006; 17(7): 1120 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Zhang, Y. Wang, R. Yao, R. A. Lubet, and M. You p53 Transgenic Mice Are Highly Susceptible to 4-Nitroquinoline-1-Oxide-Induced Oral Cancer Mol. Cancer Res., June 1, 2006; 4(6): 401 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Neugut, M. Matasar, X. Wang, R. McBride, J. S. Jacobson, W.-Y. Tsai, V. R. Grann, and D. L. Hershman Duration of Adjuvant Chemotherapy for Colon Cancer and Survival Among the Elderly J. Clin. Oncol., May 20, 2006; 24(15): 2368 - 2375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yang, C. E. Bohl, V. A. Nair, S. M. Mustafa, S. S. Hong, D. D. Miller, and J. T. Dalton Preclinical Pharmacology of a Nonsteroidal Ligand for Androgen Receptor-Mediated Imaging of Prostate Cancer J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 402 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Anderson, J. S. Jacobson, D. F. Heitjan, J. G. Zivin, D. Hershman, A. I. Neugut, and V. R. Grann Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med, March 21, 2006; 144(6): 397 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gelbard, C. T. Garnett, S. I. Abrams, V. Patel, J. S. Gutkind, C. Palena, K.-Y. Tsang, J. Schlom, and J. W. Hodge Combination Chemotherapy and Radiation of Human Squamous Cell Carcinoma of the Head and Neck Augments CTL-Mediated Lysis. Clin. Cancer Res., March 15, 2006; 12(6): 1897 - 1905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bratasz, N. M. Weir, N. L. Parinandi, J. L. Zweier, R. Sridhar, L. J. Ignarro, and P. Kuppusamy Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin PNAS, March 7, 2006; 103(10): 3914 - 3919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Wiseman, C. Baliski, R. Irvine, D. Anderson, G. Wilkins, D. Filipenko, H. Zhang, and S. Bugis Hemithyroidectomy: The Optimal Initial Surgical Approach for Individuals Undergoing Surgery for a Cytological Diagnosis of Follicular Neoplasm Ann. Surg. Oncol., March 1, 2006; 13(3): 425 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Pectasides, M. Pectasides, and T. Economopoulos Brain metastases from epithelial ovarian cancer: a review of the literature. Oncologist, March 1, 2006; 11(3): 252 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Becton, G. V. Dahl, Y. Ravindranath, M. N. Chang, F. G. Behm, S. C. Raimondi, D. R. Head, K. C. Stine, N. J. Lacayo, B. I. Sikic, et al. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421 Blood, February 15, 2006; 107(4): 1315 - 1324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
International Breast Cancer Study Group Randomized Trial Comparing Axillary Clearance Versus No Axillary Clearance in Older Patients With Breast Cancer: First Results of International Breast Cancer Study Group Trial 10-93 J. Clin. Oncol., January 20, 2006; 24(3): 337 - 344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Tassi, R. T. Henke, E. T. Bowden, M. R. Swift, D. P. Kodack, A. H. Kuo, A. Maitra, and A. Wellstein Expression of a Fibroblast Growth Factor-Binding Protein during the Development of Adenocarcinoma of the Pancreas and Colon Cancer Res., January 15, 2006; 66(2): 1191 - 1198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Valmori, F. Qian, M. Ayyoub, C. Renner, A. Merlo, S. Gjnatic, E. Stockert, D. Driscoll, S. Lele, L. J. Old, et al. Expression of Synovial Sarcoma X (SSX) Antigens in Epithelial Ovarian Cancer and Identification of SSX-4 Epitopes Recognized by CD4+ T Cells Clin. Cancer Res., January 15, 2006; 12(2): 398 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fiore, P. G. Casali, R. Miceli, L. Mariani, R. Bertulli, L. Lozza, P. Collini, P. Olmi, C. Mussi, and A. Gronchi Prognostic Effect of Re-Excision in Adult Soft Tissue Sarcoma of the Extremity Ann. Surg. Oncol., January 1, 2006; 13(1): 110 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. d. O. Santos, C. R. Cernea, M. Inoue, and A. R. Ferraz Selective Neck Dissection for Node-Positive Necks in Patients With Head and Neck Squamous Cell Carcinoma: A Word of Caution Arch Otolaryngol Head Neck Surg, January 1, 2006; 132(1): 79 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gronborg, T. Z. Kristiansen, A. Iwahori, R. Chang, R. Reddy, N. Sato, H. Molina, O. N. Jensen, R. H. Hruban, M. G. Goggins, et al. Biomarker Discovery from Pancreatic Cancer Secretome Using a Differential Proteomic Approach Mol. Cell. Proteomics, January 1, 2006; 5(1): 157 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wang, J. Hayashi, and G. Serrero PC Cell-Derived Growth Factor Confers Resistance to Dexamethasone and Promotes Tumorigenesis in Human Multiple Myeloma Clin. Cancer Res., January 1, 2006; 12(1): 49 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Suzuki, Y. Daigo, N. Ishikawa, T. Kato, S. Hayama, T. Ito, E. Tsuchiya, and Y. Nakamura ANLN Plays a Critical Role in Human Lung Carcinogenesis through the Activation of RHOA and by Involvement in the Phosphoinositide 3-Kinase/AKT Pathway Cancer Res., December 15, 2005; 65(24): 11314 - 11325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kitagawa, J. Dai, J. Zhang, J. M. Keller, J. Nor, Z. Yao, and E. T. Keller Vascular Endothelial Growth Factor Contributes to Prostate Cancer-Mediated Osteoblastic Activity Cancer Res., December 1, 2005; 65(23): 10921 - 10929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Stearman, L. Dwyer-Nield, L. Zerbe, S. A. Blaine, Z. Chan, P. A. Bunn Jr., G. L. Johnson, F. R. Hirsch, D. T. Merrick, W. A. Franklin, et al. Analysis of Orthologous Gene Expression between Human Pulmonary Adenocarcinoma and a Carcinogen-Induced Murine Model Am. J. Pathol., December 1, 2005; 167(6): 1763 - 1775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nathansohn, J. Schachter, and H. Gutman Patterns of Recurrence in Patients With Melanoma After Radical Lymph Node Dissection Arch Surg, December 1, 2005; 140(12): 1172 - 1177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Munden, S. S. Swisher, C. W. Stevens, and D. J. Stewart Imaging of the Patient with Non-Small Cell Lung Cancer Radiology, December 1, 2005; 237(3): 803 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-Y. Lee, S.-H. Oh, J. K. Woo, W.-Y. Kim, C. S. Van Pelt, R. E. Price, D. Cody, H. Tran, J. M. Pezzuto, R. M. Moriarty, et al. Chemopreventive Effects of Deguelin, a Novel Akt Inhibitor, on Tobacco-Induced Lung Tumorigenesis J Natl Cancer Inst, November 16, 2005; 97(22): 1695 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fan, M. Zhou, M. K. Pathak, D. J. Lindner, C. Z. Altuntas, V. K. Tuohy, E. C. Borden, and T. Yi Sodium Stibogluconate Interacts with IL-2 in Anti-Renca Tumor Action via a T Cell-Dependent Mechanism in Connection with Induction of Tumor-Infiltrating Macrophages J. Immunol., November 15, 2005; 175(10): 7003 - 7008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-M. Tu, J. Kim, L. C. Pagliaro, F. Vakar-Lopez, F. C. Wong, S. Wen, R. General, D. A. Podoloff, S.-H. Lin, and C. J. Logothetis Therapy Tolerance in Selected Patients With Androgen-Independent Prostate Cancer Following Strontium-89 Combined With Chemotherapy J. Clin. Oncol., November 1, 2005; 23(31): 7904 - 7910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yamamoto, Y. Tomita, T. Uruno, Y. Hoshida, Y. Qiu, N. Iizuka, I. Nakamichi, A. Miyauchi, and K. Aozasa Increased Expression of Valosin-Containing Protein (p97) Is Correlated With Disease Recurrence in Follicular Thyroid Cancer Ann. Surg. Oncol., November 1, 2005; 12(11): 925 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fabbri, D. Iliopoulos, F. Trapasso, R. I. Aqeilan, A. Cimmino, N. Zanesi, S. Yendamuri, S.-Y. Han, D. Amadori, K. Huebner, et al. WWOX gene restoration prevents lung cancer growth in vitro and in vivo PNAS, October 25, 2005; 102(43): 15611 - 15616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gallardo, B. Rubio, L. Villanueva, and O. Barajas Gallbladder Cancer, a Different Disease that Needs Individual Trials J. Clin. Oncol., October 20, 2005; 23(30): 7753 - 7754. [Full Text] [PDF]
|
|
|
|
 |
|
 R Houghton and G Rottenberg Testicular lumps Imaging, October 1, 2005; 17(2): 101 - 112. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH | TABLE OF CONTENTS |
Uterus cancer death rates are for uterine cervix and uterine corpus combined.
The rate for local stage represents local and regional stages combined.
Statistic could not be calculated.